| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Revenue | 217 | 221 | - | |
| Research and development | 26,821 | 25,882 | - | |
| General and administrative | 11,935 | 14,048 | - | |
| Total operating expenses | 38,756 | 39,930 | - | |
| Operating loss | -38,539 | -39,709 | - | |
| Interest income | 3,258 | 3,593 | 4,027 | |
| Interest expense | 2 | 1 | - | |
| Net loss before income taxes | -35,283 | -36,117 | 0 | |
| Income tax expense (benefit) | 560 | 848 | - | |
| Net loss before noncontrolling interest | -35,843 | -36,965 | - | |
| Basic eps | - | - | -0.13 | |
| Diluted eps | - | - | -0.13 | |
| Basic average shares | - | - | 128,976,366 | |
| Diluted average shares | - | - | 128,976,366 | |
| Earnings per share, basic, total | -0.12 | - | - | |
| Earnings per share, diluted, total | -0.12 | - | - | |
| Weighted average number of shares outstanding, basic, total | 134,992,796 | - | - | |
| Weighted average number of shares outstanding, diluted, total | 134,992,796 | - | - | |
PROKIDNEY CORP. (PROK)
PROKIDNEY CORP. (PROK)